Analysis of the Current Status of CRS Due to Pediatric ALL Treated with CAR-T Therapy

Abstract

Chimeric antigen receptor (CAR)-T therapy has been a popular treatment for tumors in recent years, and it has good efficacy for pediatric acute lymphoblastic leukemia (ALL), especially B-lymphoblastic ALL. Generally, CAR-T therapy affects the tumor immune microenvironment and activates the immune response, so it may lead to the occurrence of inflammation and some other adverse effects, most of which are self-limiting symptoms. However, a small number of children will develop severe cytokine release syndrome (CRS), which may be life-threatening in severe cases. Currently, the main means of treating or alleviating CRS is the application of monoclonal antibodies, glucocorticosteroids, boosting drugs, etc. Although these drugs can relieve symptoms, further effects need to be further discussed. The mechanism of CAR-T causing ALL is described in this paper, and the mechanism, advantages and disadvantages of various drugs, and their impact on tumor treatment are compared to analyze the better measures to deal with CRS, so as to provide ideas for further clinical practice.